Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Two months after postponing offer, Celladon nets $44.3mm in refiled Nasdaq IPO

Executive Summary

Celladon Corp. (calcium dysregulation therapeutics) netted $44.3mm in its IPO, selling 6.3mm shares (including the overallotmnet) at $8, a steep decline from its proposed $14-16 range announced in November 2013, shortly before it postponed the offer (originally filed in October 2013) citing poor market conditions.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies